Vtv Therapeutics to start PhIII test of diabetes drug in Q2
Vtv Therapeutics has submitted an application to the FDA to initiate the first Phase III trial to assess the efficacy and safety of the company’s lead compound, cadisegliatine, in the treatment of type 1 diabetes, a press release from the company states.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.